Proactive Investors - Run By Investors For Investors

MGC Pharmaceuticals rockets up 37% after reimbursement win for cannabis epilepsy therapeutic

The company has started manufacturing the product and plans to launch it later this year.
ASX gainer
MGC’s shares beat a declining broader market during trading today

MGC Pharmaceuticals Ltd (ASX:MXC) added 31.37% to its share price after its CannEpil medical cannabis product received an Australian Therapeutic Goods Administration approval to be prescribed for reimbursement to people with drug-resistant epilepsy.

The European company expects to make its reimbursable cannabis product available to the Australian market in December 2018 through pharmaceutical distributor HL Pharma.

A ‘validation’ of strategy

MGC Pharmaceuticals co-founder and managing director Roby Zomer said: “We are delighted to announce the availability of our first product CannEpil for supply under the Authorised Prescriber Scheme.

“This is a significant achievement for us and we are very excited at the prospect of ramping up production to a commercial scale and bringing CannEpil to Australia.

“This important step validates MXC’s seed-to-pharma strategy with the start of commercial revenues from our first investigational medicinal product offering.”

The company’s core business strategy is to develop and supply high-quality cannabinoid-based pharmaceutical products to medical markets in Europe, North America and Australasia.

MGC Pharmaceuticals tipped today it expects $1 million of annualised revenue from an initial base of 100 patients.

Earlier this year the company raised $5 million to build a fully-licensed medical cannabis facility in Malta to manufacture the clinically-tested therapeutic.

The company is one of a handful of companies to be awarded a full medical cannabis production and cultivation contract by the small European Union member.

A ‘milestone’ for people with epilepsy

Epilepsy Action Australia chief executive officer Carol Ireland welcomed the adding of CannEpil to Australia’s Authorised Prescriber Scheme.

Ireland said: “This is a significant milestone for epilepsy patients and other patient communities.

“It is another important step in improving access to potentially life-changing medications, and part of a global trend to recognise the valid medical benefits of cannabis.”

Ireland pointed to a global shift in focus towards patient rights and said today’s development was a “sign that patient needs and wants are (being) heard and respected.”

MGC Pharmaceuticals’ shares gained up to 1.6, or 31.37% today, to close at 6.7 cents. The company’s securities regularly changed hands for 7 cents during the trading day, frequently resting up 37.26%.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MXC profile View Profile

MGC Pharmaceuticals Ltd Timeline

Related Articles

Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry
1540909388_Marijuana-stethoscope.jpg
October 31 2018
The firm wants to become the first publicly listed, globally focused, pure cannabis company
The Green Organic Dutchman windmill in a field
Thu
TGOD has been building out its facilities in Ontario, Quebec, and Jamaica, expecting to reach combined production of 170,000 kilograms of cannabis around 2020

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use